Therapeutic Potential of Iron Chelators in Cancer Therapy
The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.
Abstract
The success of DFO at markedly inhibiting the growth of aggressive tumors such as neuroblastoma and leukemia justifies interest in the development of chelators as anti-neoplastic agents. This is emphasized by the fact that DFO has suboptimal properties, namely poor membrane permeability and a very short serum half-life. More recently, the thiosemicarbazone chelator, Triapine, has entered a phase I clinical trial again confirming the potential of these compounds. Further studies examining the effects of chelators on neoplastic cells will not only be valuable in terms of identifing novel anti-cancer agents, but will also provide new information on the role of Fe in cell cycle control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It follows that cancer cells are more sensitive to iron deprivation than normal cells and may therefore be susceptible to treatment with iron chelators [61].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [61]
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Cloning and characterization of a mammalian proton-coupled metal-ion transporter
Gunshin, H., Mackenzie, B., Berger, U. V., Gunshin, Y., Romero, M. F., Boron, W. F., Nussberger, S., Gollan, J. L., & Hediger, M. A. (1997) · Nature · doi:10.1038/41343 · Cited by 3,166
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
The ferritins: molecular properties, iron storage function and cellular regulation
Harrison, P. M., & Arosio, P. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00022-9 · Cited by 2,667
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Hentze, M. W., & Kühn, L. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8175 · Cited by 1,292
Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
Fleming, M. D., Trenor, C. C., Su, M. A., Foernzler, D., Beier, D. R., Dietrich, W. F., & Andrews, N. C. (1997) · Nature Genetics · doi:10.1038/ng0897-383 · Cited by 1,159
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Research works printed but not linked: 6
- Richardson, D.R., 1997, Iron chelators as effective anti-proliferative agentsCan. J. Physiol. Pharmacol.75:1164. · doi:10.1139/y97-156 · Paper page
- Beckloff, G.L., Lerner, H.1., Frost, D., Russo-Alesi, F.M., and Gitomer, S., 1965, Hydroxyurea (NSC-32065) in biological fluids: Dose-concentration relationshipCancer Chemother. Rep.48:57.
- Brodie, C., Siriwardana, G., Lucas, J., Schleicher, R., Terada, N., Szepesi, A., Gelfand, E., and Seligman, P., 1993, Neuroblastoma sensitivity to growth inhibition by deferoxamine: Evidence for a block in the GIphase of the cell cycleCancer Res.53: 3968.
- Blatt, J., and Stitely, S., 1987, Antineuroblastoma activity of desferrioxamine in human cell linesCancer Res.47:1749.
- Hoyes, K.P., Hider, R.C., and Porter, J.B., 1992, Cell cycle synchronization and growth inhibition by 3hydroxypyridin-4-one iron chelators in leukemic cell linesCancer Res.52: 4591.
- Bi, S., Hughes, T., Bungey, J., Chase, A., de Fabritiis, P., and Goldman, J.A., 1992, sp53 in chronic myeloid leukemia cell lineLeukemia6: 839
Cited by
Lysosomes in iron metabolism, ageing and apoptosis
Kurz, T., Terman, A., Gustafsson, B., & Brunk, U. T. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0394-y · Cited by 302
“Encouraging therapeutic results have been obtained in clinical phase III studies using iron chelators, which seem to have a selective effect on tumor cells, while not harming normal ones that also need iron, e.g., erythroblasts (Richardson 2002).”
BackgroundLysosomes and oxidative stress in aging and apoptosis
Kurz, T., Terman, A., Gustafsson, B., & Brunk, U. T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.01.009 · Cited by 287
Ribonucleotide Reductase Inhibitors and Future Drug Design
Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723949 · Cited by 284
“Therefore, iron chelators are of value as therapeutic agents in the treatment of cancer [290, 291].”
BackgroundActivation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis
O'Donnell, K. A., Yu, D., Zeller, K. I., Kim, J.-W., Racke, F., Thomas-Tikhonenko, A., & Dang, C. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2373-2386.2006 · Cited by 253
“Desferrioxamine (DFX) is a potent iron chelator that has been shown to inhibit the growth of aggressive tumors, such as neuroblastoma and leukemia (3, 4, 46) and is currently used to treat iron-overload disorders (45).”
BackgroundSynthetic and natural iron chelators: Therapeutic potential and clinical use
Hatcher, H. C., Singh, R. N., Torti, F. M., & Torti, S. V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.121 · Cited by 242
Metadata
- Authors
- Richardson, D. R.
- Affiliations
- The Heart Research Institute (AU)
- Corresponding author
- Richardson, Des R.
- ORCID
- Richardson, Des R.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer US
- Published
- 2002
- Volume
- 509
- Pages
- 231-249
- ISSN
- 0065-2598 (ISSN-L)
- OpenAlex
- W61704258
- Cited by
- 40
- References
- 108
- Citations by year
- 2022: 1 · 2021: 3 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 3 · 2013: 2 · 2012: 1
- FWCI
- 8.02
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- iron chelators, cancer therapy, deferoxamine, oral iron chelators, iron metabolism
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Deferoxamine, Humans, Iron, Iron Chelating Agents, Isoniazid, Neoplasms, Pyridoxal, Thiosemicarbazones, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Potential of Iron Chelators in Cancer Therapy. https://app.cochat.ai/papers/10.1007/978-1-4615-0593-8_12
- The paper
- Richardson, D. R. (2002). Therapeutic Potential of Iron Chelators in Cancer Therapy. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-1-4615-0593-8_12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.